コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 uction cycle 1, 183 after cycle 2, 124 after consolidation therapy).
2 o receive G-CSF through 2 monthly courses of consolidation therapy.
3 dose treatment versus conventional doses for consolidation therapy.
4 es of 250 mg/m(2), and was continued through consolidation therapy.
5 o assess HRQOL at end of induction and after consolidation therapy.
6 spectively, in 141 and 102 HR patients after consolidation therapy.
7 received up to four cycles of pemetrexed as consolidation therapy.
8 ve, and 26 remain progression free after ICE consolidation therapy.
9 and were eligible to receive their assigned consolidation therapy.
10 ICE (ifosfamide, carboplatin, and etoposide) consolidation therapy.
11 se of HDAC followed by alternative intensive consolidation therapy.
12 cal trials and were assigned to receive HDAC consolidation therapy.
13 trexate [HDMTX]; 2.5 or 5.0 g/m2 per day) as consolidation therapy.
14 ctive initial therapy and further studies of consolidation therapy.
15 ieved by increased anthracycline dose during consolidation therapy.
16 e alone followed 2 months later by rituximab consolidation therapy.
17 -alpha transcript by the completion of their consolidation therapy.
18 ease, as determined by flow cytometry, after consolidation therapy (100% positive predictive value).
19 logeneic transplantation compared with other consolidation therapies (5-year OS, 54.7% v 0%; Mantel-B
20 and ASCT are both feasible and effective as consolidation therapies after high-dose methotrexate-bas
21 urrent data fail to support a clear role for consolidation therapy after chemoradiotherapy; however,
22 nd studies investigating the role of SIRT as consolidation therapy after chemotherapy are needed.
23 ion was retained despite readministration as consolidation therapy after double autologous transplant
24 phalan plus stem-cell transplantation or MPR consolidation therapy after induction, and 251 patients
26 1 years for patients who received interferon consolidation therapy and 3.2 years for patients who wer
27 ogression received an additional 3 months of consolidation therapy and then 4 months of maintenance t
28 mission could be treated with five cycles of consolidation therapy and up to 12 months of maintenance
30 new regimens for induction of remission and consolidation therapy, and bone-marrow transplantation h
31 solidation therapy, standard-dose cytarabine consolidation therapy, and high-dose cytarabine consolid
32 l transplantation, as well as into post-ASCT consolidation therapy, and in the maintenance setting.
34 te remission (CR) were treated with HD Ara-C consolidation therapy as a method of in vivo purging bef
35 solidation therapy, and high-dose cytarabine consolidation therapy before HLA-identical sibling trans
36 tients who had a complete remission received consolidation therapy consisting of one cycle of treatme
38 severe gastrointestinal (GI) toxicity during consolidation therapy containing mercaptopurine, and rem
39 r placebo; those who were in remission after consolidation therapy entered a maintenance phase in whi
40 rity of the patients who underwent high-dose consolidation therapy experienced relapse and died with
41 ncreasing evidence that the use of high-dose consolidation therapy followed by autologous hematopoiet
42 as attained the patients received 2 weeks of consolidation therapy followed by continuation therapy.
43 f children undergoing remission induction or consolidation therapy for acute lymphoblastic leukemia,
44 creased cumulative dose of idarubicin during consolidation therapy for adult AML resulted in improved
45 olerated by patients receiving induction and consolidation therapy for AML; however, there was no eff
46 urrent data support the use of AHCT as early consolidation therapy for PTCL patients who are chemosen
48 domide, and dexamethasone (KTd) as induction/consolidation therapy for transplant-eligible patients w
49 mab is also being studied in CLL patients as consolidation therapy for treatment of minimal residual
50 en randomized trial to compare bortezomib as consolidation therapy given after high-dose therapy and
54 affected by the duration of on-therapy VR or consolidation therapy (>6 months in all studies).
55 (IFM) decided to evaluate RVD induction and consolidation therapies in a sequential intensive strate
56 the efficacy of a single cycle of ATO-based consolidation therapy in a treatment regimen designed to
57 fore investigated the value of bone-targeted consolidation therapy in selected patients with advanced
58 as induction therapy, followed by intensive consolidation therapy, in inducing complete remission to
59 ogamicin (GO anti-CD33 monoclonal antibody); consolidation therapy included three additional courses
62 her-dose methotrexate (> or = 1 g/m2) during consolidation therapy may be useful in the treatment of
64 ths later by 4 weekly doses of rituximab for consolidation therapy or sequential fludarabine alone fo
65 ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induct
66 ple was available for analysis at the end of consolidation therapy, overall survival at 3 years was 4
67 ual disease (MRD) at the end of induction or consolidation therapy predicts poor outcome because chil
68 on therapy after chemoradiotherapy; however, consolidation therapy remains an option for patients who
71 g/m2 to CEM followed by autologous HSCT as a consolidation therapy resulted in 16% toxic mortality in
72 were randomly assigned to (90)Y-ibritumomab consolidation therapy (rituximab 250 mg/m(2) days -7 and
75 O(3) consolidation to standard induction and consolidation therapy significantly improves event-free
76 f patients with AML in first CR receiving no consolidation therapy, standard-dose cytarabine consolid
77 e identified within 4 months after induction-consolidation therapy, suggesting that this time frame m
80 R-mismatched NK cells in a phase II trial as consolidation therapy to decrease relapse without increa
82 ompletion of induction, transplantation, and consolidation therapy was 58%, 70%, and 87%, respectivel
86 of CR patients who did not go on to protocol consolidation therapy was more than twice as high after
87 fication (DI) phase after standard induction/consolidation therapy was previously shown to improve ou
89 ll in complete remission after two cycles of consolidation therapy were then randomly assigned to mai
90 ives of this prospective randomized study of consolidation therapy were to evaluate recurrence-free s
91 l transplantation, patients proceeded to KTd consolidation therapy, where the target doses of carfilz
92 poietic cell transplantation (AHCT) as early consolidation therapy will be the focus of this review.
94 s induction therapy for 2 weeks, followed by consolidation therapy with 200 mg/day for an additional
95 nduction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and ma
98 Neoadjuvant therapy before cystectomy and consolidation therapy with biological agents after first
99 e randomly assigned to receive two cycles of consolidation therapy with cytarabine 100 mg/m(2) daily
100 topenia and thrombocytopenia after intensive consolidation therapy with diaziquone (AZO) and mitroxan
101 ded four- or five-agent remission induction; consolidation therapy with doxorubicin, vincristine, cor
102 on therapy with three cycles of RVD and then consolidation therapy with either five additional cycles
107 therapy with daunorubicin and cytarabine and consolidation therapy with high-dose cytarabine) plus ei
109 sponse to initial therapy, they proceeded to consolidation therapy with melphalan, etoposide, TBI, an
110 ileukemic activity of standard induction and consolidation therapy with or without the addition of th
113 usion, combination of standard induction and consolidation therapy with sorafenib in the schedule inv
114 , and daunorubicin, followed by 2 courses of consolidation therapy with tretinoin plus daunorubicin,
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。